#6500 MULTICENTER RETROSPECTIVE STUDY TO ASSESS THE CLINICAL PRESENTATION AND OUTCOME OF SARS-COV2 INFECTION IN PATIENTS WITH LUPUS NEPHRITIS

Le résumé fourni par la source

Abstract Background and Aims The present study aims to describe the clinical presentation and outcome of SARS-CoV2 infection in patients with systemic lupus erythematosus (SLE) and renal involvement (LN). Method 82 patients with biopsy-proven LN were retrospectively studied. 56 (68.3%) had a positive test for SARS-CoV2 at some point during the follow up time and were compared with 26 patients with SLE patients who had LN but were not infected with SARS-CoV2 in oedr toexplore the impact of SARS-CoV2 infection in the outcome of LN. Patients who had reached end-stage kidney disease before infection were excluded. Biopsy data, treatment, outcome of LN, clinical presentation of SARS-CoV2 infection and outcome were recorded. Results The mean age of the patients was 33 (±12.7) years and 85.3% were females. In the histopathological diagnosis there was proliferative LN in 43 (76.8%) cases. All patients had received immunosuppressive therapy and 89.2% had achieved remission of LN. 66.1% of patients were treated with immunosuppressive agenst at the time of diagnosis of the SARS-CoV2 infection. 94.6% of patients were tested due to symptoms while gradually all of the patients became symptomatic. 5 (9.01%) of patients required hospitalization mainly due to hypoxemia. 11 (19.6%) of patients received specific treatment for SARS-CoV2 infection, 91.6% of patients experienced complete recovery, 2 (3.57%) experienced prolonged symptomatology, and 1 (1,785%) died. 10.9% of patients with SARS-CoV2 infection, who were in remission before infection, experienced a relapse of LN in a mean time of 2.7(±2.1) months after the infection, while none of the patients without SARS-CoV2 infection relapsed in the same time period (p = 0.09). Conclusion SARS-CoV2 infection affects the morbidity of patients with SLE who have renal involvement and possibly the likelihood of relapse in those who have achieved remission prior to infection.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.